• Vulnerability of healthy vertebrae in patients with and without previous vertebral fracture Mario E. Morosano , Inés Menoyo, Digna A. Caferra, Ariel Sánchez,María F. Tomat,Roberto Bocanera, Stella M. Pezzotto, Ana M. Masoni  Bone 48 (2011) 820–827
   

• Osteoporosis in inflammatory joint diseases  C. Roux Osteoporos Int (2011) 22:421–43
   

• Osteoblast physiology in normal and pathological conditions Anna Neve ,Addolorata Corrado. Francesco Paolo Cantatore Cell Tissue Res DOI 10.1007/s00441-010-1086-1
   

• Long-Term Use of Bisphosphonates in Osteoporosis Nelson B. Watts and Dima L. Diab J. Clin. Endocrinol. Metab. 2010 95:1555-1565
   

• Atypical Subtrochanteric and Femoral Shaft Fractures in Bisphosphonate Users: Five Years and Counting, Yet Still Too Many Unanswered Questions   IBMS BoneKEy. 2010 September;7(9):296-303 http://www.bonekey-ibms.org/cgi/content/full/ibmske;7/9/296 doi: 10.1138/20100462
   

• Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research Running Title: Atypical Femoral Fractures Task Force Report  Elizabeth Shane (Co-Chair), David Burr (Co-Chair), Peter R. Ebeling, Bo Abrahamsen, Robert A. Adler, Thomas D. Brown, Angela M. Cheung, Felicia Cosman, Jeffrey R. Curtis, Richard Dell, David Dempster, Thomas A. Einhorn, Harry K. Genant, Piet Geusens, Klaus Klaushofer, Kenneth Koval, Joseph M. Lane, Fergus McKiernan, Ross McKinney, Alvin Ng, Jeri Nieves, Regis O’Keefe, Socrates  Papapoulos, Howe Tet Sen, Marjolein C.H. van der Meulen, Robert S. Weinstein, Michael Whyte Journal of Bone and Mineral Research  DOI 10.1002/jbmr.253
   

• Epidemiology, costs and burden of osteoporosis in Mexico Patricia Clark , Fernando Carlos, José Luis Vázquez Martínez Arch Osteoporo DOI 10.1007/s11657-010-0042-8.
   

• Vitamina D:  Actualización Ariel Sanchez Mev. Med. Rosario 76: 70-87, 2010
   

• Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis  Santiago Palacios  Current Medical Research & Opinion Vol. 26, No. 7, 2010, 1553–1563
   

• A rational approach to management of alendronate-related subtrochanteric fractures  S. Das De, T. Setiobudi, L. Shen, S. Das De   J Bone Joint Surg [Br] 2010;92-B:679-86.
   

• Clinical Trial Evaluation :  Interest of lasofoxifene in the treatment of osteoporosis Evaluation of ‘Lasofoxifene in postmenopausal women with osteoporosis.’ N Engl J Med 2010;362:686-96  Jean-Yves Reginster  Expert Opin. Pharmacother. (2010) 11(10)
   

• Stroke in relation to use of raloxifene and other drugs against osteoporosis P. Vestergaard , K. Schwartz , E. M. Pinholt  L. Rejnmark. L. Mosekilde   Osteoporos Int DOI 10.1007/s00198-010-1276-4
   

• Bone Material Quality in Transiliac Bone Biopsies of postmenopausal Osteoporotic Women After 3 Years of Strontium Ranelate Treatment  Paul Roschger, Inderchand Manjubala, Norbert Zoeger, Florian Meirer Rolf Simon, Chenghao Li, Nadja Fratzl-Zelman , Barbara M Misof , Eleftherios P Paschalis, Christina Streli , Peter Fratzl , and Klaus Klaushofer  Journal of Bone and Mineral Research, Vol. 25, No. 4, April 2010, pp 891–900
   

• Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. H. M. Macdonald , K. K. Nishiyama , D. A. Hanley , S. K. Boyd   Osteoporos Int DOI 10.1007/s00198-010-1226-1
   

• Cost-Effectiveness of Fracture Prevention in Men Who Receive Androgen Deprivation Therapy for Localized Prostate Cancer Kouta Ito, MD, MS; Elena B. Elkin, PhD; Monica Girotra, MD; and Michael J. Morris, MD  Annals of Internal Medicine 2010;152:621-629.
   

• Subtrochanteric Femoral Fractures in Patients Receiving Long-Term Alendronate Therapy: Imaging Features   Sarah Shock Chan1 Zehava Sadka Rosenberg1 Keith Chan Craig Capeci   AJR 2010; 194:1581–1586
   

• Bisphosphonate adverse effects, lessons from large databases Bo Abrahamsen Current Opinion in Rheumatology 2010, 22:000–000, DOI:10.1097/BOR.0b013e32833ad677

• Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis  A. D. Anastasilakis  , K. A. Toulis  , D. G. Goulis  , S. A. Polyzos  , S. Delaroudis  , A. Giomisi, E. Terpos  Horm Metab Res 2009; 41: 721 – 729
   

• Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur  Dennis M. Black, Ph.D., Michael P. Kelly, M.D., Harry K. Genant, M.D., Lisa Palermo, M.A., Richard Eastell, M.D., Christina Bucci-Rechtweg, M.D., Jane Cauley, Ph.D., Ping Chung Leung, M.D., Steven Boonen, M.D., Ph.D., Arthur Santora, M.D., Anne de Papp, M.D., and Douglas C. Bauer, M.D., for the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees N Engl J Med 2010; 362:1761-1771, March 24, 2010.
  

• Lasofoxifene in Postmenopausal Women with Osteoporosis Cummings S. R., Ensrud K., Delmas P. D., LaCroix A. Z., Vukicevic S., Reid D. M., Goldstein S., Sriram U., Lee A., Thompson J., Armstrong R. A., Thompson D. D., Powles T., Zanchetta J., Kendler D., Neven P., Eastell R., the PEARL Study Investigators
  N Engl J Med 2010; 362:686-696, Feb 25, 2010. Original Articles
   

• Another Selective Estrogen-Receptor Modulator for Osteoporosis  Becker C. N Engl J Med 2010; 362:752-754, Feb 25, 2010. Editorials
   

• The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial  G.J. van Londen,S. Perera, K.T. Vujevich, S.M. Sereika, R. Bhattacharya, S.L. Greenspan  Bone (2009), doi:10.1016/j.bone.2009.10.019
   

• Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years J.Y. Reginster, O. Bruyère, A. Sawicki, A. Roces-Varela, P. Fardellone, A. Roberts, J.P. Devogelaer  Bone 45 (2009) 1059–1064
   

• Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Sarah J. Glover, Richard Eastell, Eugene V. McCloskey, Angela Rogers, Patrick Garnero,Jonathan Lowery, Rossella Belleli, Timothy M. Wright, Markus R. John. Bone 45 (2009) 1053–1058
   

• Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1 Year Compared With Historical Placebo Nelson B. Watts,, Jacques P. Brown, and Gary Cline   Journal of Clinical Densitometry: Assessment of Skeletal Health, 2009,  DOI: 10.1016/j.jocd.2009.09.005
   

• Evidence for anti-osteoporosis therapy in acute fracture situations—Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Jörg Goldhahn, David Little, Paul Mitchell, Nicola Fazzalari, Ian R. Reid, Per Aspenberg, David Marsh.  Bone (2009), doi:10.1016/j.bone.2009.10.004
   

• Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body. Yan Chevalier,Evelyn Quek, Babul Borah, Gary Gross, John Stewart, Thomas Lang, Philippe Zysset.. Bone (2009),doi:10.1016/j.bone.2009.09.032
   

• Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. Steven R. Cummings, M.D., Javier San Martin, M.D., Michael R. McClung, M.D., Ethel S. Siris, M.D., Richard Eastell, M.D., Ian R. Reid, M.D., Pierre Delmas, M.D., Ph.D., Holly B. Zoog, Ph.D., Matt Austin, M.S., Andrea Wang, M.A., Stepan Kutilek, M.D., Silvano Adami, M.D., Ph.D., Jose Zanchetta, M.D., Cesar Libanati, M.D., Suresh Siddhanti, Ph.D., and Claus Christiansen, M.D., for the FREEDOM Trial* N Engl J Med 2009;36 Aug 11, 2009 (0.1056/NEJMoa0809493)
   

• Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer  Matthew R. Smith, M.D., Ph.D., Blair Egerdie, M.D., Narciso Hernández Toriz, M.D., Robert Feldman, M.D.,Teuvo L.J. Tammela, M.D., Fred Saad, M.D., Jiri Heracek, M.D., Ph.D., Maciej Szwedowski, M.D., Chunlei Ke, Ph.D., Amy Kupic, M.A., Benjamin Z. Leder, M.D., and Carsten Goessl, M.D., for the Denosumab HALT Prostate Cancer Study Group* N Engl J Med 2009;36 Aug 11,2009 (0.1056/NEJMoa0809003).

• Diferences in persistence, safety and eficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis  Johann D. Ringe, Gerd Möller  Rheumatol Int  DOI 10.1007/s00296-009-0940-5
   

• Editorial : The National Osteoporosis Guideline Group’s new guidelines: what is new? M. Bukhari Rheumatology 2009;48:327–329 doi:10.1093/rheumatology/ken454  Advance Access publication 7 January 2009
   

• Bifosfonatos asociado a osteonecrosis de los maxilares. Revisión de la literatura Jaimes M, Oliveira GR, Olate S, Albergaria Barbosa JR de  Avances en Odontoestomatología Vol. 24 - Núm. 3 - 2008
   

• Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw.  ALIYA A. KHAN, GEORGE K.B. SÁNDOR, EDWARD DORE, ARCHIBALD D. MORRISON, MAZEN ALSAHLI, FAIZAN AMIN, EDMUND PETERS, DAVID A. HANLEY, SULTAN R. CHAUDRY, DAVID W. DEMPSTER, FRANCIS H. GLORIEUX, ALAN J. NEVILLE, REENA M. TALWAR, CAMERON M. CLOKIE, MAJD AL MARDINI, TERRI PAUL, SUNDEEP KHOSLA, ROBERT G. JOSSE, SUSAN SUTHERLAND, DAVID K. LAM, ROBERT P. CARMICHAEL, NICK BLANAS, DAVID KENDLER, STEVEN PETAK, LOUIS GEORGES ST-MARIE, JACQUES BROWN, A. WAYNE EVANS, LORENA RIOS, and JULIET E. COMPSTON   The Journal of Rheumatology 2008; 35:7, 1391-1397
   

• Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis(HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
  David M Reid, Jean-Pierre Devogelaer, Kenneth Saag, Christian Roux, Chak-Sing Lau, Jean-Yves Reginster, Philemon Papanastasiou, Alberto Ferreira, Florian Hartl, Taiwo Fashola, Peter Mesenbrink, Philip N Sambrook, for the HORIZON investigators. Lancet 2009; 373: 1253–63
   

• Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR. Osteoporos Int DOI 10.1007/s00198-009-0917-y  Apr 2009
   
• Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Paul Shekelle, MD, PhD; Robert Hopkins Jr., MD; Mary Ann Forciea, MD; and Douglas K. Owens, MD, MS, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians  Ann Intern Med. 2008;149:404-415
   
• Vitamin D deficiency: a worldwide problem with health consequences
  Michael F Holick and Tai C Chen  Am J Clin Nutr 2008;87(suppl):1080S– 6S.
   
• Nonfatal Fall-Related Injuries Associated with Dogs and Cats — United States, 2001–2006
  Department of health and human services Centers for Disease Control and Prevention
  Morbidity and Mortality Weekly Report  vol 58 no. 11 277-281, March 27,2009
   
• The Effects of Tibolone in Older Postmenopausal Women
  Steven R. Cummings, M.D., Bruce Ettinger, M.D.,Pierre D. Delmas, M.D., Ph.D., Peter Kenemans, M.D., Ph.D., Victoria Stathopoulos, Ph.D., Pierre Verweij, Ph.D., Mirjam Mol-Arts, M.D., Lenus Kloosterboer, Ph.D., Lori Mosca, M.D., Ph.D., M.P.H., Claus Christiansen, M.D., John Bilezikian, M.D., Eduardo Mario Kerzberg, M.D., Susan Johnson, M.D., Jose Zanchetta, M.D., Diederich E. Grobbee, M.D., Ph.D., Wilfried Seifert, Ph.D., and Richard Eastell, M.D., for the LIFT Trial Investigators* N Engl J Med 2008;359:697-708.
   
• Bisphosphonate nephrotoxicity  Mark A. Perazella and Glen S. Markowitz  Kidney International advance online publication, 6 August 2008; doi:10.1038/ki.2008.356
   
• REVIEW ARTICLE: Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis
  William Strampel, Ronald Emkey and Roberto Civitelli Drug Safety 2007; 30 (9): 755-763
   
• Increase in Bone Mass after correction of Vitamin D Insufficiency in Biphosphonate-Treated Patients
  Jordan L Geller, MD, Bei Hu, Ba,  Susan Reed, RN, James Mirocha, MS John S Adams,MD Endocrine Practice  vol 14 no. 3 April 2008 293-297
   
• Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture
  Suzanne M. Cadarette, PhD; Jeffrey N. Katz, MD, MS; M. Alan Brookhart, PhD; Til Stu¨ rmer, MD, MPH; Margaret R. Stedman, MPH; and Daniel H. Solomon, MD, MPH  Ann Intern Med. 2008;148:637-646.
   
• Nota aclaratoria: Con relación a las publicaciones recientes sobre Fibrilación Auricular asociada al uso de FOSAMAX:  Laboratorios Merck Sharp  & Dhome -México
   
• Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians
  Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Paul Shekelle, MD, PhD; Robert Hopkins Jr., MD; Mary Ann Forciea, MD; and Douglas K. Owens, MD, MS, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians Ann Intern Med. 2008;148:680-684.
   
• ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
  Eric J. MacLaughlin and Cynthia L. Raehl Am J Health-Syst Pharm. 2008; 65:343-57
   
• Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
  Susan R. Heckbert, MD, PhD; Guo Li, MS; Steven R. Cummings, MD; Nicholas L. Smith, PhD; Bruce M. Psaty, MD, PhD  Arch Intern Med. 2008;168(8):826-831
   
• Osteoprotegerin, Thiazolidinediones Treatment, and Silent Myocardial Ischemia in Type 2 Diabetic Patients
  ARIANE SULTAN, MD ANTOINE AVIGNON, MD FLORENCE GALTIER, MD CHRISTOPHE PIOT, MD DENIS MARIANO-GOULART, MD ANNE MARIE DUPUY, MD JEAN PAUL CRISTOL, MD   DIABETES CARE, VOLUME 31, NUMBER 3, MARCH 2008
   
• Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients.A case-control study
  MATTEO MONAMI, MD, PHD BARBARA CRESCI, MD ANGELA COLOMBINI, MD LAURA PALA, MD DANIELA BALZI, MD FRANCESCA GORI, MD VERONICA CHIASSERINI, MD NICCOL `O MARCHIONNI, MD CARLO MARIA ROTELLA, MD  EDOARDO MANNUCCI, MD Diabetes Care 31:199–203, 2008
   
• The Peroxisome Proliferator-Activated Receptor- Agonist Rosiglitazone Decreases Bone Formation and
  Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial.  Andrew Grey, Mark Bolland, Greg Gamble, Diana Wattie, Anne Horne, James Davidson, and Ian R. Reid, J Clin Endocrinol Metab 92: 1305–1310,
  2007

• Use of Thiazolidinediones and Fracture Risk Christian Meier, MD; Marius E. Kraenzlin, MD; Michael Bodmer, MD;
  Susan S. Jick, DSc; Hershel Jick, MD; Christoph R. Meier, PhD  Arch Intern Med. 2008;168(8):820-825
   
• Review: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues Kathryn M. Thrailkill, Charles K. Lumpkin, Jr., R. Clay Bunn, Stephen F. Kemp, and John L. Fowlkes. Am J Physiol Endocrinol Metab 289: E735–E745, 2005.
   
• Editorial: Bona Fide Genetic Associations with Bone Mineral Density
  Joel N. Hirschhorn, M.D., Ph.D., and Luigi Gennari, M.D., Ph.D. N Engl J Med 10.1056/nejme0803046
   
• Multiple Genetic Loci for Bone Mineral Density and Fractures
  Unnur Styrkarsdottir, Ph.D., Bjarni V. Halldorsson, Ph.D.,Solveig Gretarsdottir, Ph.D., Daniel F. Gudbjartsson, Ph.D.,
  G. Bragi Walters, B.Sc., Thorvaldur Ingvarsson, M.D., Ph.D.,Thorbjorg Jonsdottir, B.Sc., Jona Saemundsdottir, B.Sc., Jacqueline R. Center, M.B., B.S., Ph.D., Tuan V. Nguyen, Ph.D., Yu Bagger, M.D., Jeffrey R. Gulcher, M.D., Ph.D., John A. Eisman, M.B., B.S., Ph.D., Claus Christiansen, M.D., Gunnar Sigurdsson, M.D., Ph.D., Augustine Kong, Ph.D., Unnur Thorsteinsdottir, Ph.D., and Kari Stefansson, M.D., Ph.D.  N Engl J Med 2008;358.
   

• Position Paper:
  European guidance for the diagnosis and management of osteoporosis in postmenopausal women
  J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli,  Osteoporos Int (2008) 19:399–428 DOI 10.1007/s00198-008-0560-z
  on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
   

• FRAX™ and the Assessment of Fracture Probability: An Introduction
  John A. Kanis, Anders Oden, Helena Johansson, and Eugene McCloskey  IBMS BoneKEy. 2008 March;5(3):114-117 http://www.bonekey-ibms.org/cgi/content/full/ibmske;5/3/114 doi: 10.1138/20080305
  WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom

• Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure Robert R Recker, , Pierre D Delmas, , Johan Halse, , Ian R Reid, , Steven Boonen, , Pedro A García-Hernandez, , Jerzy Supronik, , E Michael Lewiecki, , Luis Ochoa, , Paul Miller, , Huilin Hu, , Peter Mesenbrink, , Florian Hartl, , Juerg Gasser, , Erik F Eriksen, Journal of Bone and Mineral Research,  January 2008:23:6-16
   

• Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis Lan-Juan Zhao, , Hui Jiang, , Christopher J Papasian, , Dev Maulik, , Betty Drees, , James Hamilton, , Hong-Wen Deng, Journal of Bone and Mineral Research, January 2008:23:17-29
   

• Use of Oral Bisphosphonates and the Risk of Aseptic Osteonecrosis: A Nested Case-Control Study Mahyar Etminan, Kevin Aminzadeh, Ian R. Matthew and James M. Brophy  The Journal of Rheumatology 2008; 35:3
   

• Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. P. Clark , F. Carlos , C. Barrera , J. Guzman ,A. Maetzel , P. Lavielle , E. Ramirez , V.Robinson,R. Rodriguez-Cabrera , J. Tamayo , P. Tugwell . Osteoporos Int DOI 10.1007/s00198-007-0496-8  (Diciembre 2007)
   

• Development and Internal Validation of the Male Osteoporosis Risk Estimation Score. Angela J. Shepherd, Alvah R. Cass, Carol A. Carlson, Laura Ray, Ann Fam Med 2007;5:540-546. 10.1370/afm.753.
   

• Individualization of osteoporosis risk . T. V. Nguyen  Osteoporos Int (2007) 18:1153–1156
   

• Vertebral dimensions as risk factor of vertebral fracture in osteoporotic patients: a systematic literature review. A. Ruyssen-Witrand , L. Gossec , S. Kolta ,M. Dougados , C.Roux Osteoporos Int (2007) 18:1271–1278 
   

• Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club
  J. J. Body, P. Bergmann, S. Boonen , Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. Y. Reginster, S. Rozenberg, J. M. Kaufman
  Osteoporos Int (2007) 18:1439–1450
   

• Incidence of second hip fractures. A population-based study 
  E. Lönnroos, H. Kautiainen, P. Karppi, S. Hartikainen, I. Kiviranta, R. Sulkava 
  Osteoporos Int (2007) 18:1279–1285
   

• Excess mortality following hip fracture: the role of underlying health status
  A. N. A. Tosteson, D. J. Gottlieb, D. C. Radley, E. S. Fisher, L. J. Melton III
  Osteoporos Int (2007) 18:1463-1472
   

• Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis
  J. P. Devogelaer, J. P. Brown , P. Burckhardt , P. J. Meunier , S. Goemaere , K. Lippuner , J. J. Body ,G. Samsioe , D. Felsenberg , T. Fashola , L. Sanna ,C. E. Ortmann , U. Trechsel ,J. Krasnow , E. F. Eriksen , P. Garnero.
  Osteoporos Int (2007) 18:1211–1218
   

• Review :  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
  E. Seeman  Bone 41 (2007) 308–317 ,
   

• Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture  Kenneth W. Lyles, M.D., Cathleen S. Colón-Emeric, M.D., M.H.Sc., Jay S. Magaziner, Ph.D., Jonathan D. Adachi, M.D., Carl F. Pieper, D.P.H., Carlos Mautalen, M.D., Lars Hyldstrup, M.D., D.M.Sc., Chris Recknor, M.D., Lars Nordsletten, M.D., Ph.D., Kathy A. Moore, R.N., Catherine Lavecchia, M.S., Jie Zhang, Ph.D., Peter Mesenbrink, Ph.D., Patricia K. Hodgson, B.A., Ken Abrams, M.D., John J. Orloff, M.D., Zebulun Horowitz, M.D., Erik  Fink Eriksen, M.D., D.M.Sc., and Steven Boonen, M.D., Ph.D., for the HORIZON Recurrent Fracture Trial*
  N Engl J Med 2007;357.   September 17, 2007.
   

• Hip fractures in users of first- vs. second-generation bisphosphonates  M. Mamdani  A. Kopp  G. Hawker
  Osteoporosis Int  DOI 10.1007/s00198-007-0446-5
   

• Cultural adaptation and validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) in a Mexican population  Esperanza Ramírez Pérez, Patricia Clark, Niels H. Wacher, Mario H. Cardiel , Ma. del Pilar Diez García Clin Rheumatol  DOI 10.1007/s10067-007-0661-7, 2007
   

• Cost-effectiveness of Bone Densitometry Followed by Treatment of Osteoporosis in Older Men John T. Schousboe, MD, MS Brent C. Taylor, PhD, MPH, Howard A. Fink, MD, MPH, Robert L. Kane, MD, Steven R. Cummings, MD , Eric S. Orwoll, MD, L. Joseph Melton III, MD, MPH, Douglas C. Bauer, MD, Kristine E. Ensrud, MD, MPH   JAMA, August 8, 2007—Vol 298, No. 6, 629-637
   

• Review : Osteoporosis in Patients With Diabetes Mellitus Lorenz C Hofbauer, Carolin C Brueck, Shiv K Singh, and Harald Dobnig J Bone Miner Res 2007;22:1317–1328. Published online on May 14, 2007; doi: 10.1359/JBMR.070510

•  

• Decision Rules for Selecting Women for Bone Mineral Density Testing: Application in Postmenopausal Women Referred to a Bone Densitometry Unit
  Dolores Martinez-Aguila, Carmen Gomez-Vaquero, Antoni Rosadilla, Montserrat Romera, Javier Narvaez  and Joan M. Nolla. J Rheumatol 2007;34:1307–12)
   

• Technical White Paper: Bone Densitometry  June Hawkinson, BS, RT(R), Julie Timins, MD, Dennis Angelo, MS,Margaret Shaw, RT(R), Russell Takata, MPH, Frances Harshaw, BS,
   J Am Coll Radiol 2007;4:320-327.
   

• Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
     Dennis M. Black y cols New England Journal of Medicine Volume 356:1809-1822 May 3, 2007 Number 18
   

• Implementation of a Mandatory Rheumatology Osteoporosis Consultation in Patients With Low-Impact Hip Fracture.
  Anne-Marie Quintos-Macasa, MD, Robert Quinet, MD, Malik Spady, MD, Jerald Zakem, MD,William Davis, MD, Yamini Menon, MD, Leonard Serebro, MD, and M. A. Krousel-Wood, MD, MSPH
  J Clin Rheumatol 2007;13: 70–72
   

• Risedronate Reduces Postoperative Bone Resorption After Cementless Total Hip Arthroplasty
  S. Yamasaki, K. Masuhara, K. Yamaguchi, T. Nakai, T. Fuji, Y. Seino  Osteoporos Int (2007) 18:1009–1015
   

• Osteoporosis
  Lee S. Simon, MD Rheum Dis Clin N Am 33 (2007) 149–176

            Asociación Mexicana de Metabolismo Óseo y Mineral A.C.
                        Durango 269 oficina 6, 3er piso Colonia Roma, Delegación Cuauhtémoc
                                  México DF CP 06700   Tel y FAX: 01(55) 55-11-72-60  
                            web:www.ammom.com.mx e-mail: ammomcentral@prodigy.net.mx
                            Webmaster: Dr. Fidencio Cons Molina  fcons@ammom.com.mx 
  

                               Responsable del mantenimiento de esta página:
                             Dr. Fidencio Cons Molina  fcons@ammom.com.mx